Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC).
D. Jelovac
No relevant relationships to disclose
D. K. Armstrong
Consultant or Advisory Role - Abraxis BioScience; Amgen; Astellas Pharma; Boehringer Ingelheim; Celgene; Genentech; Genzyme; Morphotek; Oncogenex; VentiRx
Research Funding - Agensys; Astellas Pharma; Morphotek
S. Weil
Employment or Leadership Position - Morphotek
Other Remuneration - Morphotek
M. Phillips
Employment or Leadership Position - Morphotek
B. M. Schwartz
Research Funding - Morphotek
J. M. Estes
No relevant relationships to disclose
R. D. Alvarez
Research Funding - Morphotek